type of carbapenemase also affects the response to therapy with at least one new antimicrobial, ceftazidime-avibactam. As a consequence, molecular analysis of pathogens may assist clinicians in their choice of optimal antimicrobial therapy for serious CRE-related infections, such as HAP/VAP [4] .
Microbiology laboratories now have the option to use commercially available Food and Drug Administration-approved realtime polymerase chain reaction assays targeting the 5 most common carbapenemase genes KPC, New Delhi metallo-B-lactamase-1 (NDM-1), imipenemase (IMP), Verona imipenemase (VIM), and OXA-48. In addition, timely carbapenem MIC testing by E-test can be performed, offering precise carbapenem MIC values. Identification of metallo-β-lactamases alerts the infectious disease clinician against the use of ceftazidime-avibactam, which is inactive against metallo-β-lactamases such as NDM-1, VIM and IMP. A further potentially confounding factor is the detection of CRE isolates in the United States with ceftazidime-avibactam MIC values ≥8 µg/mL, associated with the presence of the KPC gene bla kpc-2 [7] . Therefore, determining the MIC for ceftazidime-avibactam is critical to guiding antibiotic therapy. The availability of this information in the first 24 hours after the isolation of a CRE facilitates an educated treatment decision by the infectious disease clinician. The predicted impact of molecular resistance testing on patient outcomes, however, remains to be demonstrated in clinical trials.
In addition to potentially improved outcomes associated with carbapenemcontaining combination therapy, such an approach may be important in deterring the emergence of resistance to polymyxins, the propensity for which is enhanced in the face of monotherapy [8] . Polymyxin monotherapy also raises concern about the accelerated spread of plasmid-mediated polymyxin resistance especially because mcr-1 has been detected in organisms carrying carbapenemases, including New Delhi metallo-β-lactamase [9] . These observations indicate that strong consideration should be given to the optimization of laboratory evaluation and the use of combination antibiotic therapy in patients with HAP/ VAP due to CRE. 
